產品名稱：Adalimumab ELISA Kit

Adalimumab ELISA Kit is a quantitative ELISA kit for detection of Adalimumab.

Adalimumab is a recombinant human IgG1 monoclonal antibody specific for Tumor Necrosis Factor-Alpha (TNF-a) and is used to treat rheumatic arthritis, intestinal disorders, dermatological diseases and cancer. Adalimumab specifically binds to TNF alpha and blocks its interaction with p55 and p75 cell surface TNF receptors and reduces the inflammation and subsequently improves the patient’s health. Drug level quantification can be important to adapt patient prescription or to switch to an alternative TNF inhibitor drug.

Target	Adalimumab
Reactivity	Human
Tested Applications	ELISA
Recommended dilutions	Optimal dilutions/concentrations should be determined by the end user.
Storage	Shipped at 4 °C. Upon receipt, store the kit according to the storage instruction in the kit's manual.
Validity	The validity for this kit is 6 months.
Stability	The stability of the kit is determined by the rate of activity loss. The loss rate is less than 5% within the expiration date under appropriate storage conditions. To minimize performance fluctuations, operation procedures and lab conditions should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same user throughout.
Test Range	0.31 μg/ml - 5 μg/ml
Sensitivity	0.16 μg/ml
Standard Form	Lyophilized
Detection Method	Colorimetric
Assay Type	Competitive
Assay Data	Quantitative
Sample Type	Serum and plasma.
CAS Number	331731-18-1
Availability	Shipped within 10-20 working days.
Note	This product is for research use only. The range and sensitivity is subject to change. Please contact us for the latest product information. For accurate results, sample concentrations must be diluted to mid-range of the kit. If you require a specific range, please contact us in advance or write your request in your order comments. Please note that our ELISA and CLIA kits are optimised for detection of native samples, rather than recombinant proteins. We are unable to guarantee detection of recombinant proteins, as they may have different sequences or tertiary structures to the native protein.

Research Articles on Adalimumab